



FOR IMMEDIATE RELEASE

## 6 of the Top 20 Global Pharmaceutical Companies Standardizing on Veeva Vault QMS

*More than 175 companies adopt Vault QMS to streamline end-to-end quality processes*

**BARCELONA, Spain — 12 May 2021** — Leading companies continue to prioritize the modernization of quality management. With this shift well underway, six of the top 20 global pharmaceutical companies have partnered with **Veeva Systems** (NYSE: VEEV) to standardize on **Veeva Vault QMS** for greater efficiency and better visibility across the enterprise. A growing number of organizations, including more than 175 biopharma, contract manufacturers, generics, and medtech companies, have adopted Vault QMS to streamline and automate quality processes.

"As a long-standing partner, Veeva has been collaborating closely with us on our digital quality initiatives," said Nicolás Maldonado, senior director, quality policies and systems at Gilead Sciences. "We are excited to bring in Veeva Vault QMS to simplify, harmonize, and automate quality processes across multiple strategic businesses within Gilead."

More organizations are adopting Veeva's modern cloud solutions to bring together quality processes for greater transparency and real-time visibility across global sites, manufacturing partners, and suppliers. Industry leaders are partnering with Veeva to simplify quality management and increase operational efficiency with a unified quality platform.

"Companies want a trusted partner that remains focused on customer success for digital quality transformation," said Mike Jovanis, vice president, Veeva Vault Quality. "Veeva is committed and will continue to deliver customer-focused innovation across product development and manufacturing."

Veeva's continuous innovation is helping customers proactively manage quality and increase agility. Over the last year, new features for Vault QMS include:

- Seamless connection between Vault QMS and **Veeva Vault Registrations** to reduce cycle time and increase transparency within post-market change control
- Quality Risk Management (QRM) advancements, including FMEA methodology to support proactive identification and mitigation of risks
- Fully automated process for external auditees such as CMOs and suppliers to respond to audit findings directly within the system

Vault QMS is part of the **Veeva Vault Quality Suite**, including **Veeva Vault QualityDocs**, **Veeva Vault Training**, **Veeva Vault Station Manager**, and **Veeva Vault Product Surveillance** to automate and harmonize quality processes globally.

In other news today, Veeva announced that Bluepharma selected Vault Quality Suite to unify global quality management. Read the [press release](#) for more information.

Learn more about Vault Quality Suite at the upcoming **Veeva R&D and Quality Summit Connect Europe**, 20 May 2021. The online event is open to life sciences industry professionals. Register and stay up to date on program details at [veeva.com/Summit](https://veeva.com/Summit).

### Additional Information

For more on Veeva Vault QMS, visit: [veeva.com/QMS](https://veeva.com/QMS)

Connect with Veeva on LinkedIn: [linkedin.com/company/veeva-systems](https://linkedin.com/company/veeva-systems)

Follow @veeva\_eu on Twitter: [twitter.com/veeva\\_eu](https://twitter.com/veeva_eu)

### About Veeva Systems

Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 975 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit [veeva.com/eu](https://veeva.com/eu).

### **Forward-looking Statements**

This release contains forward-looking statements, including the market demand for and acceptance of Veeva's products and services, the results from use of Veeva's products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva's historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva's expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva's financial results are included under the captions, "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations," in the company's filing on Form 10-K for the period ended January 31, 2021. This is available on the company's website at [veeva.com](https://veeva.com) under the Investors section and on the SEC's website at [sec.gov](https://sec.gov). Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

###

### **Contact:**

Deivis Mercado  
Veeva Systems  
925-226-8821  
[deivis.mercado@veeva.com](mailto:deivis.mercado@veeva.com)